Vertex Pharmaceuticals does not trade like a drug company sitting still. Third-quarter revenue came in at $3.44 billion, up 12% year over year, and the company raised its full-year guidance to between $13.15 billion and $13.25 billion. Those numbers landed four days ago and the stock edged higher. What the market is really pricing now is what happens on November 30.
The BLA for povetacicept in IgA nephropathy is under FDA priority review with a PDUFA date of November 30, 2026. The submission rests on positive data from a pre-specified interim analysis of the ongoing Phase 3 RAINIER trial. If approved, povetacicept becomes the first commercialized therapy in Vertex’s nephrology franchise. Management’s tone on the earnings call was unambiguous: “We are 100% ready, and we are incredibly excited to bring povitacept to patients with IgAN.”
The strategic logic here is what distinguishes VRTX from most large-cap biotech. Rare endocrine is now the fourth commercial pillar, and with the PDUFA date later this month for povetacicept in IgA nephropathy, Vertex plans to soon establish its fifth in renal. Each pillar is funded by the same source: cystic fibrosis. CF generated about $3.44 billion in Q3 alone, up 12% year over year. That franchise does not cycle with the economy, does not depend on insurance cycle shifts the way primary care does, and throws off enough cash to absorb a $10 billion acquisition without breaking a sweat.
Vertex did take on a $4.5 billion term loan to fund the Crinetics acquisition, with staggered maturities of $1 billion in 2027, $1 billion in 2028, and $2.5 billion in 2029. That is real debt, and it helps explain why GAAP earnings per share missed estimates in Q3 even as revenue beat. But with non-GAAP gross margin at 85.6% in Q3, the underlying cash generation capacity remains nearly unmatched in biotech.
Beyond nephrology, two other lines matter for traders watching the next six months. CASGEVY saw 30% revenue growth quarter over quarter, and JOURNAVX prescriptions exceeded 750,000 in Q3. Phase 3 enrollment in suzetrigine for diabetic peripheral neuropathy is expected to complete by end of 2026, which would open a chronic pain indication far larger than the acute pain launch Vertex is already executing.
The near-term trade is binary in one narrow sense: povetacicept approval on November 30 is the catalyst, and the stock has already moved roughly 15% since late July in anticipation. Short interest sits at just 1.7% of shares outstanding, so there is no meaningful squeeze potential and no large skeptic overhang to unwind if approval comes.
The question is simpler: does a company generating over $13 billion annually in revenue, expanding into five distinct disease areas, with an 85%-plus gross margin and a kidney drug decision in 24 days, deserve more attention than it is getting? The CF engine says yes. November 30 will say how much.
Vertex is not alone in proving that specialty medicine margins can absorb large legal or acquisition charges. GSK’s Q3 showed a £2.1 billion free cash flow quarter even after absorbing a $2.2 billion Zantac settlement charge.
